口腔臨床營養市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球口腔臨床營養市場價值為 322 億美元，預計將以 5.5% 的複合年成長率成長，到 2034 年達到 540 億美元。

癌症、糖尿病、胃腸道疾病和慢性阻塞性肺病 (COPD) 等疾病增加了營養管理的需求。口服臨床營養產品通常用於支持康復和維持營養狀態。

標準配方奶粉使用率上升

標準配方奶粉市場在2024年保持了永續的佔有率，這得益於其能夠滿足各種一般營養需求的多功能性。這些配方奶粉適用於不需要特定疾病配方但仍需要高熱量和營養補充品的患者。醫院、門診和長期照護機構通常會開立標準配方奶粉，用於術後恢復、短期營養不良和一般飲食支持。

成年人採用率不斷提高

由於慢性病發病率上升、與老化相關的營養挑戰以及人們對疾病相關營養不良的認知不斷提高，成人市場在2024年佔據了相當大的佔有率。接受癌症治療、術後復健或治療糖尿病和胃腸道疾病等疾病的成年人通常需要口服營養支持來維持體重和功能狀態。

營養不良問題將受到重視

2024年，營養不良領域收入可觀，這得益於臨床和老年護理機構的支持。儘管營養不良是一種可預防和可治療的疾病，但它仍然診斷不足，尤其是在老年人和慢性病患者中。市場對旨在解決蛋白質-能量營養不良和微量營養素缺乏症的針對性口服營養補充劑的需求激增。

北美將成為利潤豐厚的地區

受人口老化、高昂的醫療支出以及強大的臨床基礎設施的推動，北美口服臨床營養市場預計在2025-2034年期間實現可觀的複合年成長率。主要市場參與者的加入，加上優惠的報銷政策和完善的分銷網路，進一步推動了該地區的成長。此外，大眾和專業人士對營養在慢性病管理中重要性的認知不斷提高，也加速了口服營養補充品的普及。

口腔臨床營養產業的主要參與者包括明治控股、輝瑞、Nutriset、雅培營養、大塚製藥、Kate Farms、B. Braun、葛蘭素史克、雀巢健康科學、AYMES Nutrition、達能、Medifood International、費森尤斯卡比和美贊臣（利潔時）。

為了鞏固其在口服臨床營養市場的立足點，各公司正在採取一系列措施，包括產品創新、策略合作夥伴關係和地理擴張。領先的製造商正在大力投資研發，以開發針對特定疾病的配方，以滿足糖尿病、腎臟病或癌症患者的獨特飲食需求。此外，各品牌也著重口味改善和便利性，例如即飲型，以提高患者的依從性。與醫院、家庭醫療保健提供者和保險公司的策略合作有助於擴大市場覆蓋範圍並提高產品的可及性。這些策略共同使公司能夠保持競爭優勢，同時滿足不同患者群體不斷變化的營養需求。

目錄

第1章：方法論與範圍

第 2 章：執行摘要

第3章：行業洞察

• 產業生態系統分析
  • 供應商格局
  • 每個階段的增值
  • 影響價值鏈的因素
• 產業衝擊力
  • 成長動力
    • 與疾病相關的營養不良和慢性病發病率不斷上升
    • 老年人口不斷增加
    • 納入臨床指引
    • 個人化營養的進步
  • 產業陷阱與挑戰
    • 專業產品成本高
    • 認知和篩檢有限
  • 市場機會
    • 家庭醫療保健的擴展
    • 技術整合
• 成長潛力分析
• 監管格局
  • 北美洲
  • 歐洲
  • 亞太地區
  • 世界其他地區
• 管道分析
• 定價分析
• 差距分析
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 關鍵進展
  • 併購
  • 夥伴關係與協作
  • 新產品發布
  • 擴張計劃

第5章：市場估計與預測：按產品，2021 - 2034 年

• 主要趨勢
• 標準公式
• 針對特定疾病的配方

第6章：市場估計與預測：按消費者，2021 - 2034 年

• 主要趨勢
• 兒科
• 成人

第7章：市場估計與預測：按應用，2021 - 2034

• 主要趨勢
• 癌症護理
• 慢性腎臟病
• 糖尿病
• 胃腸道疾病
• 營養不良
• 其他應用

第8章：市場估計與預測：按劑型，2021 - 2034

• 主要趨勢
• 液體
• 粉末
• 半固體

第9章：市場估計與預測：按配銷通路，2021 - 2034 年

• 主要趨勢
• 線下通路
  • 醫院藥房
  • 零售藥局
  • 其他線下通路
• 線上通路

第 10 章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：公司簡介

• Abbott Nutrition
• AYMES Nutrition
• B. Braun
• Danone
• Fresenius Kabi
• GlaxoSmithKline
• Kate Farms
• Mead Johnson (Reckitt)
• Medifood International
• Meiji Holdings
• Nestle Health Science
• Nutriset
• Otsuka Pharmaceutical
• Pfizer

The Global Oral Clinical Nutrition Market was valued at USD 32.2 billion in 2024 and is estimated to grow at a CAGR of 5.5% to reach USD 54 billion by 2034.

Conditions like cancer, diabetes, gastrointestinal disorders, and COPD increase the need for nutritional management. Oral clinical nutrition products are commonly used to support recovery and maintain nutritional status.

Rising Use of Standard Formula

The standard formula segment held a sustainable share in 2024, driven by its versatility in addressing a wide range of general nutritional needs. These formulas are used for patients who do not require condition-specific formulations but still need calorie-dense and nutrient-rich supplements. Hospitals, outpatient clinics, and long-term care facilities routinely prescribe standard formulas for post-operative recovery, short-term malnutrition, and general dietary support.

Increasing Adoption Among Adults

The adult segment held a sizeable share in 2024, owing to the rising incidence of chronic illnesses, aging-related nutritional challenges, and growing awareness around disease-related malnutrition. Adults undergoing cancer therapy, recovering from surgery, or managing conditions like diabetes and gastrointestinal disorders often require oral nutrition support to maintain body mass and functional status.

Malnutrition to Gain Traction

The malnutrition segment generated notable revenues in 2024, backed by clinical and elderly care settings. Despite being a preventable and treatable condition, malnutrition remains underdiagnosed, especially among older adults and patients with chronic illnesses. The market has seen a surge in demand for targeted oral nutrition supplements designed to address protein-energy malnutrition and micronutrient deficiencies.

North America to Emerge as a Lucrative Region

North America oral clinical nutrition market is poised to witness a decent CAGR during 2025-2034, driven by an aging population, high healthcare expenditure, and robust clinical infrastructure. The presence of major market players, combined with favorable reimbursement policies and well-established distribution networks, further fuels regional growth. In addition, increasing public and professional awareness of the importance of nutrition in managing chronic diseases has accelerated the adoption of oral nutrition supplements.

Major players operating in the oral clinical nutrition industry include Meiji Holdings, Pfizer, Nutriset, Abbott Nutrition, Otsuka Pharmaceutical, Kate Farms, B. Braun, GlaxoSmithKline, Nestle Health Science, AYMES Nutrition, Danone, Medifood International, Fresenius Kabi, and Mead Johnson (Reckitt).

To strengthen their foothold in the oral clinical nutrition market, companies are pursuing a mix of product innovation, strategic partnerships, and geographic expansion. Leading manufacturers are investing heavily in R&D to develop condition-specific formulations that cater to the unique dietary needs of patients with diabetes, renal disease, or cancer. Additionally, brands are focusing on taste improvement and convenience, such as ready-to-drink formats, to boost patient compliance. Strategic collaborations with hospitals, home healthcare providers, and insurance companies have helped extend market reach and improve product accessibility. These strategies collectively enable companies to maintain a competitive advantage while addressing the evolving nutritional demands of diverse patient populations.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Product
  • 2.2.3 Consumer
  • 2.2.4 Application
  • 2.2.5 Dosage form
  • 2.2.6 Distribution channel
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factors affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of disease-related malnutrition and chronic conditions
    • 3.2.1.2 Growing elderly population
    • 3.2.1.3 Integration into clinical guidelines
    • 3.2.1.4 Advancements in personalized nutrition
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of specialized products
    • 3.2.2.2 Limited awareness and screening
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion in home healthcare
    • 3.2.3.2 Technological integration
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Rest of the world
• 3.5 Pipeline analysis
• 3.6 Pricing analysis
• 3.7 Gap analysis
• 3.8 Future market trends
• 3.9 Porter’s analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Standard formulas
• 5.3 Disease-specific formulas

Chapter 6 Market Estimates and Forecast, By Consumer, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Pediatric
• 6.3 Adult

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Cancer care
• 7.3 Chronic kidney disease
• 7.4 Diabetes
• 7.5 Gastrointestinal disorders
• 7.6 Malnutrition
• 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By Dosage Form, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Liquid
• 8.3 Powder
• 8.4 Semi-solid

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Offline channel
  • 9.2.1 Hospital pharmacies
  • 9.2.2 Retail pharmacies
  • 9.2.3 Other offline channels
• 9.3 Online channel

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Abbott Nutrition
• 11.2 AYMES Nutrition
• 11.3 B. Braun
• 11.4 Danone
• 11.5 Fresenius Kabi
• 11.6 GlaxoSmithKline
• 11.7 Kate Farms
• 11.8 Mead Johnson (Reckitt)
• 11.9 Medifood International
• 11.10 Meiji Holdings
• 11.11 Nestle Health Science
• 11.12 Nutriset
• 11.13 Otsuka Pharmaceutical
• 11.14 Pfizer